secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tourmaline Bio, Inc. (—)
CIK:        0001827506
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001104659-25-102971
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 5.01, 5.03, 3.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tourmaline Bio acquired by Novartis for $48/share; stock to be delisted
-----------------------------------------------------------------------

- Tender offer completed with 92.94% of shares tendered (24,030,382 shares).
- Merger effected under DGCL Section 251(h); all remaining shares converted to $48 cash each.
- All outstanding stock options and RSUs cashed out at same per-share value.
- All prior directors and officers resigned; Novartis appointees John McKenna and Eduard Marti now lead.
- Stock to be delisted from Nasdaq; deregistration to follow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827506/000110465925102971/0001104659-25-102971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827506/000110465925102971/tm2529486d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-102971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer